Search Results

You are looking at 61 - 70 of 126 items for :

  • "Bladder cancer" x
Clear All
Full access

Sarguni Singh, Megan Eguchi, Sung-Joon Min and Stacy Fischer

palliative care consultation remains limited for patients in SNFs. 10 We sought to understand clinical outcomes of patients with stage II–IV pancreatic, colorectal, lung, and bladder cancers who discharge to an SNF compared with patients who discharge to home

Full access

Pooja Ghatalia and Elizabeth R. Plimack

approved in the platinum-refractory second-line setting. CheckMate 275, a phase II trial, evaluated nivolumab monotherapy in 265 patients with metastatic or nonresectable platinum-resistant bladder cancer. 15 Updated results at 33.7-month follow-up were

Full access

jnccn19042 10.6004/jnccn.2019.7320 Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies Mazzone Elio a b c MD Knipper Sophie a d MD Mistretta Francesco A. a e MD Palumbo

Full access

0131151 10.6004/jnccn.2015.0140 It May Be Time to Abandon Urine Tests for Bladder Cancer Fantony Joseph J. MD Inman Brant A. MD, MS 9 2015 13 13 9 9 1163 1163 1166 1166 0131163 10.6004/jnccn.2015.0141

Full access

Richard T. Hoppe

approve IMRT for “prostate, head and neck, thyroid, central nervous system, and pediatric tumors; anal, rectal, and bladder cancers; gynecologic tumors; pelvic sarcomas; certain left breast and lung cancers.” But for mediastinal lymphoma, IMRT was

Full access

Kathleen C. a MD Carlson Robert W. b c MD Kapp Daniel S. a MD, PhD 11 2014 12 12 11 11 1537 1537 1545 1545 0121537 10.6004/jnccn.2014.0153 Predictors of Outcome in Bladder Cancer Eifler John B. a MD Barocas Daniel A. a MD

Full access

Robert J. Morgan

healthy tissue . Future Oncol 2010 ; 6 : 1043 – 1049 . 9 Williams H Pembroke A . Sniffer dogs in the melanoma clinic? Lancet 1989 ; 1 : 734 . 10 Willis CM Church SM Guest CM . Olfactory detection of human bladder cancer by

Full access

Robert W. Carlson

, breast, non–small cell lung, pancreatic, and bladder cancers, as well as chronic myeloid leukemia, sarcomas, and melanoma. NCCN experts provided guidance on complicated issues across the continuum of cancer care, such as access to emerging treatments and

Full access

: Bladder Cancer, Version 5.2018 Flaig Thomas W. 1 * MD Spiess Philippe E. 2 * MD, MS Agarwal Neeraj 3 MD Bangs Rick 4 MBA Boorjian Stephen A. 5 * MD Buyyounouski Mark K. 6 MD, MS Downs Tracy M. 7 MD Efstathiou Jason A. 8 MD, DPhil Friedlander Terence 9 MD

Full access

Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy Matulewicz Richard S. a b MD, MS Frainey Brendan T. a BS Oberlin Daniel T. a MD Meeks Joshua J. a MD, PhD 11 2016 14 14 11 11 1403 1403 1411 1411 jnccn0141403